N/A N=57 SB3 Battery Life Observational Study
Capsule Endoscopy
Primary: Completion Rate (Rate at Which Small Bowel is Completely Examined) — 57 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=566 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100) — 36; 27.9 percentage…
Phase 3 N=161 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Polycythemia Vera
Primary: Number of Participants With Adverse Events - All Grades — 143; 26 Participants
Phase 4 N=1,086 A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers
Smoking Cessation · Smoking · Nicotine Dependence
Primary: Biochemically-confirmed 7-Day Point-Prevalence Abstinence at 26 Weeks — 63; 124; 108 Participants — p=.3623
N/A N=113 To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin
Skin Care
Primary: Frequency of Combined Dermatologist Score — 1; 1; 51; 55 Participants
Phase 2 N=33 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
Psoriasis
Primary: The Mean Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI). — -25.08; -12.63 percent change — p=0.2205
Phase 2 N=690 Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
Pneumococcal Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 74.9; 72.3; 67.4 Percentage of Participants
Phase 4 N=10 Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
Vulvovaginal Atrophy · Dyspareunia
Primary: Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography — 8 points improvement on VGTA scale — p=0.05
N/A N=908 An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination
Human Papilloma Virus Vaccines · Attitude to Health
Primary: Intention to Vaccinate Against HPV in the Next 12 Months — 3.49; 3.87; 4.16 score on a scale — p=<.02
N/A N=362 Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)
Asthma
Primary: Change in Asthma Control Test Score — 3.32 change in composite score
N/A N=13,775 Amlodipine 10mg Drug Use Investigation
Hypertension
Primary: Number of Participants With Treatment Related Adverse Events — 208 participants
Phase 4 N=56 B&O for TLH Post-operative Pain and Nausea
Hysterectomy · Pain, Postoperative
Primary: Post-operative Pain: VAS — 4.1; 4.8 score on a scale — p=0.17
Phase 2 N=90 Pain Management in Children and Young Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Participants With Successful Pain Interventions by Arm Between Presentation and 3 Hours Post Administration of Study Drug — 13; 17; 27; 25 Participants — p=0.227
Phase 2 N=840 Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children
Norovirus
Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1 — 77.4; 63.5; 74.5; 85.7 percentage of participants
N/A N=248 Pain Coping Skills Training for African Americans With Osteoarthritis
Osteoarthritis
Primary: Change From Baseline to Month 3 and Change From Baseline to 9 Month in Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Pain Subscale — -1.59; -0.96…